FDA Approves New Targeted Pill for Advanced Pancreatic Cancer, Offering Patients a New Treatment Option
WASHINGTON, D.C. — A significant development in pancreatic cancer treatment has emerged in the United States after the U.S. Food and Drug Administration (FDA) approved Rasonque (daraxonrasib), a once-daily targeted tablet for certain adults with metastatic pancreatic adenocarcinoma.
The FDA announced the approval on August 26, 2026, describing the medicine as a first-in-class targeted therapy for metastatic pancreatic cancer. The treatment is intended for adults whose cancer has spread and who have already received at least one systemic therapy, or who are not candidates for multi-drug systemic treatment.
A Different Approach to Pancreatic Cancer
Rasonque works by inhibiting proteins in the RAS family, which play an important role in driving the growth of many pancreatic tumors. Unlike conventional chemotherapy, which broadly targets rapidly dividing cells, the new tablet is designed to interfere with a molecular pathway involved in cancer growth.
The recommended dose is 300 mg taken orally once a day, with treatment continuing until the disease progresses or side effects become unacceptable.
Clinical Trial Shows Survival Improvement
The FDA’s decision was supported by results from the RASolute 302 clinical trial, which enrolled 500 patients with metastatic pancreatic adenocarcinoma whose disease had progressed after one previous line of systemic therapy.
According to the FDA, patients receiving daraxonrasib had a median overall survival of 13.2 months, compared with 6.7 months among patients receiving standard chemotherapy selected by their physicians.
The trial also reported a median progression-free survival of 7.2 months, compared with 3.6 months in the standard-treatment group. The objective response rate was 30% with daraxonrasib versus 11% with standard chemotherapy.
Why the Approval Matters
Pancreatic cancer remains one of the most difficult cancers to treat. The disease is frequently diagnosed at an advanced stage, while pancreatic adenocarcinoma accounts for the overwhelming majority of pancreatic cancer cases.
The FDA said the approval came approximately 6.5 months ahead of its goal date, reflecting an accelerated review process. The application received Breakthrough Therapy and Orphan Drug designations and was also considered through the agency’s National Priority Voucher pilot program.
The FDA also reviewed the application through Project Orbis, working with Health Canada, while regulators in Europe and Japan participated as observers.
Side Effects and Safety Considerations
Although the results represent an important development, Rasonque is not without potential risks. FDA information lists possible adverse effects including rash, diarrhea, inflammation of the mouth, nausea, fatigue, vomiting, abdominal pain, swelling and reduced appetite.
The prescribing information also contains warnings concerning serious dermatologic and soft-tissue reactions, gastrointestinal complications, interstitial lung disease or pneumonitis, and embryo-fetal toxicity.
A New Chapter in Targeted Cancer Treatment
The approval does not represent a cure for pancreatic cancer, and the medicine is not intended for every patient with the disease. Instead, it adds another treatment option for a specific group of adults with advanced metastatic pancreatic adenocarcinoma.
For patients and oncologists dealing with a cancer that has historically presented major treatment challenges, the arrival of a targeted oral therapy with demonstrated survival benefits could mark an important step forward.
The FDA’s approval of Rasonque highlights the growing role of precision oncology, where treatments are increasingly designed to interfere with specific biological mechanisms that help tumors survive and grow.
